Core Viewpoint - The company, Aorite (605116.SH), has received approval from the National Medical Products Administration for a combined packaging of estradiol tablets and estradiol-dydrogesterone tablets, which is expected to enhance its market competitiveness and positively impact its financial performance [1]. Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., has obtained a drug registration certificate for the combined packaging of estradiol tablets and estradiol-dydrogesterone tablets [1]. - The approved product is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1]. - The registration of the product under the new classification method for chemical drugs is expected to improve the company's market position in this therapeutic area [1].

Group 1 - The core point of the article is that Aorite Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new drug registration certificate for a combination packaging of estradiol tablets and estradiol-dydrogesterone tablets [1] - Aorite's revenue composition for the first half of 2025 is as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trade, and 0.5% from other businesses [1] - As of the report date, Aorite's market capitalization is 8.9 billion yuan [1] Group 2 - The article also mentions that another company, identified by its stock code 688496, is under investigation by the China Securities Regulatory Commission due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases [1]

Core Viewpoint - Aorite (605116.SH) announced that its wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for a combination packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1] Group 1 - The newly approved product, branded as "Aoshutong," is classified under the new registration category for chemical drugs, which enhances the company's market competitiveness in this pharmaceutical area [1] - The approval of this product is expected to have a positive impact on the company's operational performance due to its anticipated domestic market launch [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-084 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 注册分类：化学药品4类 上市许可持有人：扬州奥锐特药业有限公司 关于全资子公司获得药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）全资子 公司扬州奥锐特药业有限公司（以下简称"扬州奥锐特"）收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的一份雌二醇片/雌二醇地屈孕酮片复 合包装（以下简称"该药品"）《药品注册证书》，现将相关情况公告如下： 一、注册证书基本信息 药品名称：雌二醇片/雌二醇地屈孕酮片复合包装 批件号：【2025S03486】 剂型：片剂 规格：雌二醇片含雌二醇2mg；雌二醇地屈孕酮片含雌二醇2mg和地屈孕酮 10mg 申请事项：药品注册（境内生产） 药品生产企业：扬州奥锐特药业有限公司 药品批准文号：国药准字H20256016 审评结论：根据《中华人民共和国药品管理法》及有关规定，经审查 ...

智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司全资子公司扬州奥锐特药业有限公司(简 称"扬州奥锐特")收到国家药品监督管理局核准签发的一份雌二醇片/雌二醇地屈孕酮片复合包装《药品 注册证书》。该药品用于治疗自然或术后绝经所致的围绝经期综合征。 本次扬州奥锐特的雌二醇片/雌二醇地屈孕酮片复合包装(注册商标"奥舒桐")按照化学药品新注册分类方 法获得药品注册批件，有利于提升公司在该药品领域的市场竞争力，同时新批准产品在国内上市销售， 有望对公司经营业绩产生积极影响。 ...

格隆汇11月21日丨奥锐特(605116.SH)公布，自2025年11月1日至2025年11月21日，公司通过上海证券交 易所交易系统以集中竞价交易方式已累计回购公司股份222.47万股，占公司目前总股本的比例为 0.55%，回购成交的最高价为22.59元/股，最低价为18.83元/股，支付的资金总额为人民币4623.11万元 （不含交易费用）。 ...

Group 1 - The company Aorite (SH 605116) announced a share buyback of approximately 2.22 million shares, representing 0.55% of its total share capital, with a total expenditure of about 46.23 million RMB [1][1][1] - The highest and lowest prices for the repurchased shares were 22.59 RMB/share and 18.83 RMB/share, respectively [1][1][1] - As of the report, Aorite's market capitalization stands at 8.9 billion RMB [1][1][1] Group 2 - For the first half of 2025, Aorite's revenue composition is as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trading, and 0.5% from other businesses [1][1][1]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2025/1/22 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 1 月 | 年 | 月 | 21 | 日~2026 | 年 | 1 | 20 日 | | 预计回购金额 | 6,000万元~12,000万元 | | | | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | | √用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计 ...

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, Aorite, and others [1]. Core Views - The pharmaceutical sector experienced a 3.29% increase this week, outperforming the CSI 300 index by 4.37 percentage points. Sub-sectors such as pharmaceutical commerce, pharmacies, and innovative drugs performed well, while medical devices and consumables lagged [2][12]. - The report emphasizes the importance of market pricing power and the impact of liquidity and risk appetite on investment strategies, particularly in innovative drugs and related supply chains [2][12]. - The report highlights the upcoming patent expirations for small molecule drugs, which are expected to create significant demand for raw materials, with a projected sales impact of $390 billion from 2025 to 2030 [3][13]. Summary by Sections Industry Performance - The pharmaceutical sector's performance this week was characterized by a 3.29% increase, with notable performances in pharmaceutical commerce (+7.31%), pharmacies (+6.83%), and innovative drugs (+5.01%). In contrast, medical devices (0.16%) and new medical infrastructure (1.18%) showed weaker performance [17][29]. - The overall price-to-earnings (P/E) ratio for the pharmaceutical industry is reported at 30.84 times, with a premium of 25.08% compared to the overall A-share market excluding the financial sector [33]. Company Dynamics - Notable company announcements include: - Prologis Pharmaceuticals received a European certificate for its product, enhancing its international market prospects [18]. - Jianyou Co. announced FDA approval for its production site, expanding its manufacturing capabilities [19]. - Fuyuan Pharmaceuticals received a drug registration certificate from the National Medical Products Administration, allowing for the marketing of its product [20]. - The report suggests focusing on companies benefiting from domestic innovative drug support policies, such as Yangguang Nuohuo and Nuosige, as well as those with strong overseas business prospects [15][7]. Raw Materials - The report indicates that the raw materials sector is expected to see a significant increase in demand due to patent expirations, with a projected sales impact of $390 billion from 2025 to 2030. The production of raw materials in H1 2025 reached 1.935 million tons, reflecting an 8.2% year-on-year increase [3][13]. - Companies recommended for attention in the raw materials sector include Aorite, Prologis Pharmaceuticals, and Aoxiang Pharmaceuticals, focusing on innovation and strong performance [3][16].

Core Points - The company will hold a Q3 2025 earnings presentation on November 24, 2025, from 13:00 to 14:00 [2][4] - The presentation will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [3][4] - Investors can submit questions from November 17 to November 21, 2025, and the company will address common concerns during the presentation [2][5] Meeting Details - The meeting is scheduled for November 24, 2025, from 13:00 to 14:00 [4] - Location: Shanghai Stock Exchange Roadshow Center [4] - Participants include the Chairman, Secretary of the Board, CFO, and Independent Director [4] Investor Participation - Investors can join the meeting online via the Shanghai Stock Exchange Roadshow Center [4] - Questions can be pre-submitted through the Roadshow Center website or via the company's email [5] - Post-meeting, the presentation details will be available on the Roadshow Center website [5]